DiaMedica Therapeutics (DMAC) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Q1 2026 results are expected after the close on May 6 with an earnings call on May 7 at 8:00 AM ET; analysts forecast EPS of ($0.17) and revenue of $13.5 million.
• In the prior quarter DiaMedica reported EPS of ($0.17), matching estimates, but revenue was just ($0.03) million versus the $13.5 million expectation, and analysts project about -$1 EPS for both the current and next fiscal year.
• Shares trade near $6.18 with a market cap of ~$333 million and a 52-week range of $3.47–$10.42; the street has a “Moderate Buy” consensus and an average price target of $12.33.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) will likely be posting its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect DiaMedica Therapeutics to post earnings of ($0.17) per share and revenue of $13.50 million for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.17) earnings per share for the quarter, meeting the consensus estimate of ($0.17). The company had revenue of ($0.03) million for the quarter, compared to analysts' expectations of $13.50 million. On average, analysts expect DiaMedica Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ:DMAC opened at $6.18 on Friday. The firm has a market capitalization of $332.98 million, a PE ratio of -8.83 and a beta of 1.00. DiaMedica Therapeutics has a 52-week low of $3.47 and a 52-week high of $10.42. The firm has a fifty day moving average of $7.00 and a 200 day moving average of $7.56.

Hedge Funds Weigh In On DiaMedica Therapeutics

Large investors have recently added to or reduced their stakes in the business. Rhumbline Advisers lifted its stake in DiaMedica Therapeutics by 14.5% in the third quarter. Rhumbline Advisers now owns 27,357 shares of the company's stock worth $188,000 after purchasing an additional 3,463 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of DiaMedica Therapeutics by 24.4% in the second quarter. BNP Paribas Financial Markets now owns 18,882 shares of the company's stock worth $74,000 after buying an additional 3,709 shares during the period. Bank of America Corp DE increased its holdings in shares of DiaMedica Therapeutics by 44.2% in the third quarter. Bank of America Corp DE now owns 12,249 shares of the company's stock worth $84,000 after buying an additional 3,752 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of DiaMedica Therapeutics in the 3rd quarter valued at about $27,000. Finally, Invesco Ltd. lifted its stake in shares of DiaMedica Therapeutics by 29.9% in the 4th quarter. Invesco Ltd. now owns 18,628 shares of the company's stock valued at $148,000 after acquiring an additional 4,293 shares during the last quarter. Hedge funds and other institutional investors own 10.12% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Lake Street Capital reaffirmed a "buy" rating on shares of DiaMedica Therapeutics in a research note on Monday, January 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of DiaMedica Therapeutics in a research report on Monday, April 20th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $12.33.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc NASDAQ: DMAC is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company's lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica's research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.